Evidence map›Paper›PMID 26075913›Full record

ArticlePloS one2015

TRAIL-Based High Throughput Screening Reveals a Link between TRAIL-Mediated Apoptosis and Glutathione Reductase, a Key Component of Oxidative Stress Response.

Dmitri Rozanov, Anton Cheltsov, Eduard Sergienko, Stefan Vasile, Vladislav Golubkov, Alexander E Aleshin, Trevor Levin, Elie Traer, Byron Hann, Julia Freimuth and 5 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Natural Agents Targeting Mitochondria in Cancer.International journal of molecular sciences · 2020
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Oxidative stress in prostate hyperplasia and carcinogenesis.Journal of experimental & clinical cancer research : CR · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 2 countries.

Dmitri RozanovDepartment of Molecular and Medical Genetics, Oregon Health and Science University, Portland, Oregon, United States of America.
Anton CheltsovQ-MOL LLC, San Diego, CA, United States of America.
Eduard SergienkoQ-MOL LLC, San Diego, CA, United States of America.
Stefan VasileThe Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, Orlando, Florida, United States of America.
Vladislav GolubkovInflammatory and Infectious Disease Center, Sanford-Burnham Medical Research Institute, La Jolla, California, United States of America.
Alexander E AleshinInflammatory and Infectious Disease Center, Sanford-Burnham Medical Research Institute, La Jolla, California, United States of America.
Trevor LevinDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, United States of America.
Elie TraerKnight Cancer Institute, Oregon Health and Science University, Portland, Oregon, United States of America.
Byron HannHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, United States of America.
Julia FreimuthHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, United States of America.
Nikita AlexeevComputational Biology Institute, George Washington University, Ashburn, Virginia, United States of America; Department of Mathematics and Mechanics, Saint Petersburg State University, Saint Petersburg, Russia.
Max A AlekseyevComputational Biology Institute, George Washington University, Ashburn, Virginia, United States of America.
Sergey P BudkoResearch Department, Shriners Hospital for Children, Portland, Oregon, United States of America; Department of Biochemistry and Molecular Biology, Oregon Health and Science University, Portland, Oregon, United States of America.
Hans Peter BächingerResearch Department, Shriners Hospital for Children, Portland, Oregon, United States of America; Department of Biochemistry and Molecular Biology, Oregon Health and Science University, Portland, Oregon, United States of America.
Paul SpellmanDepartment of Molecular and Medical Genetics, Oregon Health and Science University, Portland, Oregon, United States of America.
Oregon Health & Science University · USSanford Burnham Prebys Medical Discovery Institute · USGeorge Washington University Virginia Campus · USIn-Q-Tel · USShriners Hospitals for Children - Portland · USUCSF Helen Diller Family Comprehensive Cancer Center · USUniversity of California, San Francisco · US

Funding

Sanford-Burnham Center for Chemical GenomicsU54HG005033 · NHGRI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI JACKSON, MICHAEL · 2008 to 2012
$72.5M
SAN DIEGO CHEMICAL LIBRARY SCREENING CENTER(RMI)U54HG003916 · NHGRI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI REED, JOHN C · 2005 to 2007
$12.7M
Screening for Chemicals that Potentiate TRAIL-Induced Apoptosis of Cancer CellsR03MH081232 · NIMH · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ROZANOV, DMITRI · 2007 to 2007
$25k
NHGRI NIH HHS U54 HG003916NHGRI NIH HHS U54HG003916NHGRI NIH HHS U54 HG005033NHGRI NIH HHS U54HG005033NIMH NIH HHS R03 MH081232NIMH NIH HHS R03 MH081232-01
6 · The paper itself

Abstract

A high throughput screen for compounds that induce TRAIL-mediated apoptosis identified ML100 as an active chemical probe, which potentiated TRAIL activity in prostate carcinoma PPC-1 and melanoma MDA-MB-435 cells. Follow-up in silico modeling and profiling in cell-based assays allowed us to identify NSC130362, pharmacophore analog of ML100 that induced 65-95% cytotoxicity in cancer cells and did not affect the viability of human primary hepatocytes. In agreement with the activation of the apoptotic pathway, both ML100 and NSC130362 synergistically with TRAIL induced caspase-3/7 activity in MDA-MB-435 cells. Subsequent affinity chromatography and inhibition studies convincingly demonstrated that glutathione reductase (GSR), a key component of the oxidative stress response, is a target of NSC130362. In accordance with the role of GSR in the TRAIL pathway, GSR gene silencing potentiated TRAIL activity in MDA-MB-435 cells but not in human hepatocytes. Inhibition of GSR activity resulted in the induction of oxidative stress, as was evidenced by an increase in intracellular reactive oxygen species (ROS) and peroxidation of mitochondrial membrane after NSC130362 treatment in MDA-MB-435 cells but not in human hepatocytes. The antioxidant reduced glutathione (GSH) fully protected MDA-MB-435 cells from cell lysis induced by NSC130362 and TRAIL, thereby further confirming the interplay between GSR and TRAIL. As a consequence of activation of oxidative stress, combined treatment of different oxidative stress inducers and NSC130362 promoted cell death in a variety of cancer cells but not in hepatocytes in cell-based assays and in in vivo, in a mouse tumor xenograft model.

Indexed as

High-Throughput Screening AssaysOxidative StressAnimalsAntineoplastic AgentsApoptosisCell Line, TumorDose-Response Relationship, DrugDoxorubicinDrug DiscoveryGlutathioneGlutathione ReductaseHumansMiceReactive Oxygen SpeciesSmall Molecule LibrariesTNF-Related Apoptosis-Inducing LigandAntineoplastic AgentsDoxorubicinGlutathioneGlutathione ReductaseReactive Oxygen SpeciesSmall Molecule LibrariesTNF-Related Apoptosis-Inducing Ligand

Identifiers

PMID26075913
PMCPMC4468210
OpenAlexW565414638

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.